Biomax Informatics expands deal with Royal DSM

German R&D software firm Biomax Informatics and Dutch chemical industry giant Royal DSM plan to expand a deal under which DSM will license Biomax's BioXM system for tools used in synthetic biology research. The two companies' relationship dates back to 1998 and DSM was an early user of the BioXM system, the fourth version of which was released in March. The system simplifies the development and rollout of new life sciences applications, according to Biomax. Release

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.